Medical technology company CND Life Sciences on Thursday announced the closing of a $4.5 million Series Seed 3 equity financing round.
CND Life Sciences develops and commercializes skin-based tests for the diagnosis and treatment of neurodegenerative disorders such as Parkinson’s disease, multiple system atrophy, and Lewy body dementia. The funding is intended to accelerate the commercialization of the Syn-One test, which identifies abnormal alpha-synuclein aggregation in cutaneous nerves through skin biopsy. The Syn-One Test is supported by technology licensed from Beth Israel Deaconess Medical Center in Boston.
CND has grown from 10 employees in 2021 to over 60 in 2023; the firm opened its global headquarters and labs in Scottsdale, AZ, in March 2023. Ongoing financial support from investors has contributed to the expansion of the company as well as the commercialization of Syn-One, the firm said.
This latest round brings the firm’s seed financing to a total of $12.5 million in total equity raised.